Page last updated: 2024-12-05

beta-lapachone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beta-lapachone is a naturally occurring naphthoquinone compound found in the wood of the Lapacho tree (Tabebuia impetiginosa). It has been studied extensively for its potential anticancer activity. Beta-lapachone is a potent inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), an enzyme that plays a role in the detoxification of reactive oxygen species. By inhibiting NQO1, beta-lapachone can induce oxidative stress and cell death in cancer cells. It has also been shown to inhibit angiogenesis, the formation of new blood vessels, which is essential for tumor growth. Beta-lapachone is currently in clinical trials for the treatment of various cancers, including leukemia, melanoma, and lung cancer. Its synthesis involves several steps and typically involves the reaction of lapachol with an appropriate reagent, such as a Grignard reagent or a Wittig reagent. The importance of beta-lapachone lies in its potential as a novel anticancer agent. Its unique mechanism of action and its ability to target specific cancer cells make it a promising candidate for future cancer therapies.'

beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
TabebuiagenusA plant genus of the family BIGNONIACEAE that is a source of lapachol and beta-lapachone.[MeSH]BignoniaceaeA plant family of the order Lamiales. The family is characterized by oppositely paired, usually compound leaves and bell- or funnel-shaped, bisexual flowers having a five-lobed calyx and corolla.[MeSH]
Tabebuia avellanedaespecies[no description available]BignoniaceaeA plant family of the order Lamiales. The family is characterized by oppositely paired, usually compound leaves and bell- or funnel-shaped, bisexual flowers having a five-lobed calyx and corolla.[MeSH]

Cross-References

ID SourceID
PubMed CID3885
CHEMBL ID15192
CHEBI ID10429
SCHEMBL ID107042
MeSH IDM0063330

Synonyms (123)

Synonym
beta-lap
bdbm81348
r115 (reactive blue 2)
nsc-629749
.beta.-lapachone
nsc-26326
nsc26326
lapachone, beta
2h-naphtho[1,6-dione, 3,4-dihydro-2,2-dimethyl-
NCI60_009665
EU-0100717
beta-lapachone, >=98% (tlc)
sl 11001
2h-naphtho(1,2-b)pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-
lapachone, beta-
nsc 629749
brn 0181499
nsc 26326
3,4-dihydro-2,2-dimethyl-2h-naphtho(1,2-b)pyran-5,6-dione
BIO2_000026
NCGC00015598-01
lopac-l-2037
BIO2_000506
nsc629749
3,4-dihydro-2,2-dimethyl-2h-naphtho[1,2-b]pyran-5,6-dione
2,2-dimethyl-3,4-dihydrobenzo[h]chromene-5,6-dione
LOPAC0_000717
BCBCMAP01_000055
IDI1_033776
QTL1_000048
beta-lapachone
4707-32-8
BSPBIO_001306
NCGC00094066-04
KBIO2_002594
KBIO3_000051
KBIOSS_000026
KBIO2_000026
KBIOGR_000026
KBIO2_005162
KBIO3_000052
HSCI1_000182
NCGC00094066-03
NCGC00094066-01
NCGC00094066-02
NCGC00094066-05
arq-501
lapachone
arq 501
beta-lap-wj
mb-12066 ,
mb12066
NCGC00015598-02
HMS1989B08
NCGC00015598-08
beta lapachone
chebi:10429 ,
CHEMBL15192
HMS1361B08
HMS1791B08
AKOS005266281
HMS3262O15
unii-6n4fa2qq6a
6n4fa2qq6a ,
5-17-11-00459 (beilstein handbook reference)
A827146
2,2-dimethyl-3,4-dihydro-2h-benzo[h]chromene-5,6-dione
CCG-36362
NCGC00015598-05
NCGC00015598-03
NCGC00015598-04
NCGC00015598-07
NCGC00015598-06
FT-0635405
3,4-dihydro-2,2-dimethyl-2h-naphthol[1,2-b]pyran-5,6-dione
LP00717
S7261
smr001456339
MLS006011731
SCHEMBL107042
lapachone [inci]
beta lapachone [who-dd]
tox21_500717
CS-3680
NCGC00261402-01
?-lapachone
2,2-dimethyl-3,4-dihydro-2h-benzo[h]chromene-5,6-dione #
lapachone, .beta.
2h-naphtho[1,2-b]pyran-5,6-dione, 3,4-dihydro-2,2-dimethyl-
HY-13555
HMS3402B08
afae'a centa' nota inverted exclamation markafasa'a|afae'adaggeratrade markafa centa centasa nota em leadera inverted exclamation mark-lapachone
DTXSID90197019
AC-8965
HMS3653O04
b-lapachone
sl-11001
2,2-dimethyl-2h,3h,4h,5h,6h-naphtho[1,2-b]pyran-5,6-dione
AS-70326
SR-01000075957-1
sr-01000075957
SR-01000075957-5
SW219806-1
beta-lapachone (arq-501, co-501)
DB11948
arq-501 (beta lapachone)
Q27089386
BCP09779
(c)micro-lapachone pound>>arq 501
EX-A3011
A13059
HMS3866G13
SDCCGSBI-0050695.P003
NCGC00015598-17
arq-501;nsc-26326
C75251
2005rm01ch01
beta -lapachone
nsc813862
arq501
nsc-813862
ss-lapachone
BP-28431

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic effect of lapachol, beta-lapachone and several 1,2-naphthoquinone derivatives on the growth, viability and infectivity of Trypanosoma cruzi were compared."( In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi.
Cruz, FS; Docampo, R; Gilbert, B; Lopes, JN; Pinto, AV; Sampaio, MC; Vasconcellos, ME, 1978
)
0.55

Pharmacokinetics

ExcerptReferenceRelevance
" The validated analytical method was successfully applied to a pharmacokinetic study of a single, oral dose of 100 mg MB12066 (a clinical form of β-lapachone) in healthy volunteers."( Rapid Interference-free Analysis of β-Lapachone in Clinical Samples Using Liquid Chromatography-Mass Spectrometry for a Pharmacokinetic Study in Humans.
Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Lee, IK; Seong, SJ; Yoon, YR, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"Objective To investigate the effect and molecular mechanism of β-lapachone combined with NVP-BEZ235 on the proliferation and migration of BGC-823 human gastric cancer cells."( [β-Lapachone combined with NVP-BEZ235 inhibit proliferation and migration of BGC-823 gastric cancer cells].
Chen, L; Cui, X; Lin, Z; Sun, J; Wang, Y, 2018
)
0.48
" Probe A was selectively and efficiently sensitive to NQO1 with good safety profile and plasma stability, enabling its combination with NQO1 substrates in vivo for NQO1-overexpressing cancer theranostics for the first time."( Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics.
Gong, Q; Hu, J; Li, T; Li, X; Wang, P; Yang, F; Zhang, X, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"To explore the use of cyclodextrins (CD) to form inclusion complexes with beta-lapachone (beta-lap) to overcome solubility and bioavailability problems previously noted with this drug."( Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.
Beman, M; Boothman, DA; Bornmann, WG; Bruening, A; Gao, J; Nasongkla, N; Ray, D; Wiedmann, AF, 2003
)
0.8
" Biologic activity and bioavailability of beta-lap inclusion complexes were investigated by in vitro cytotoxicity studies with MCF-7 cells and by in vivo lethality studies with C57Blk/6 mice (18-20 g)."( Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.
Beman, M; Boothman, DA; Bornmann, WG; Bruening, A; Gao, J; Nasongkla, N; Ray, D; Wiedmann, AF, 2003
)
0.57
" However, poor aqueous solubility and low bioavailability hinder its therapeutic applications."( Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.
Ai, H; Blanco, E; Boothman, DA; Gao, J; Wang, F, 2006
)
0.72
" We also included in the analysis several β-lap derivatives expected to modify drug bioavailability and activity."( Yeast cytotoxic sensitivity to the antitumour agent β-lapachone depends mainly on oxidative stress and is largely independent of microtubule- or topoisomerase-mediated DNA damage.
Estévez-Braun, A; García-Luis, J; Lorenzo-Castrillejo, I; Machín, F; Matos-Perdomo, E; Medina-Coello, C; Quevedo, O; Ramos-Pérez, C, 2014
)
0.4
" βLAP (and its combinations with CDs) absorption rate coefficients and effective permeability values have been determined in vitro in MDCK or MDCK-Mdr1 monolayers and in situ in rat by a closed loop perfusion technique."( Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.
Bermejo, M; Casabó, VG; Echezarreta-López, M; González-Álvarez, I; González-Álvarez, M; Gutiérrez-Nieto, J; Landin, M; Mangas-Sanjuan, V, 2016
)
0.43
"The aim of this paper was to compare the in vitro dissolution and in vivo bioavailability of three solubility enhancement technologies for β-lapachone (LPC), a poorly water soluble compound with extremely high crystallization propensity."( Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Chen, H; Chen, Y; Chen, Z; Liu, C; Liu, Z; Pui, Y; Qian, F, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" A brief history of these compounds is reviewed along with their potential effects and mechanisms of action and the most recent attempts to improve their bioavailability and potency against different types of cancer."( Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues.
Ferraz da Costa, DC; Ferreira, VF; Ferretti, GDDS; Martins-Dinis, MMDDC; Pereira Rangel, L; Silva, JL, 2020
)
0.56
" β-Lapachone (BLPC) was selected for its anticancer activity and its limited bioavailability due to very low aqueous solubility, with the aim to improve this by using LAP/Tetronic nano-hybrid systems."( Nanocomposite gels of poloxamine and Laponite for β-Lapachone release in anticancer therapy.
Almeida Júnior, RF; Barbosa, RM; Câmara, CA; Câmara, GBM; de Lima E Moura, TFA; Dreiss, CA; Farias, KJS; García-Villén, F; Machado, PRL; Raffin, FN; Viseras, C, 2021
)
0.62
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022
)
0.72

Dosage Studied

beta-lapachone causes DNA strand breaks as determined by alkaline elution assay. Electron microscopy analysis showed that the frequency of the autophagosomes increased with increased dosage.

ExcerptRelevanceReference
" beta-lapachone produced DNA strand breaks as determined by alkaline elution assay; alkaline elution profiles from treated cells showed a bimodal dose-response pattern, with a threshold dose above which a massive dose-independent DNA degradation was observed."( DNA damage and cytotoxicity induced by beta-lapachone: relation to poly(ADP-ribose) polymerase inhibition.
Ceccarelli, R; Cundari, E; De Salvia, R; Degrassi, F; Fiore, M; Ricordy, R; Vanni, A, 1998
)
1.48
" Those excipients should be avoided in the development of solid dosage forms."( Compatibility of the antitumoral beta-lapachone with different solid dosage forms excipients.
Cunha-Filho, MS; Landín, M; Martínez-Pacheco, R, 2007
)
0.62
" Plasma pharmacokinetic data of ARQ 501 in mouse from intraperitoneal (IP) dosing at 60 mg/kg obtained using this validated method is presented along with tumor concentration data."( Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ARQ 501 (beta-lapachone) in plasma and tumors from nu/nu mouse xenografts.
Bailey, J; Bresciano, K; Chan, TC; Hall, T; Savage, RE; Starace, M, 2008
)
0.55
"This study provides useful information for the development of βLAP dosage forms, their storage, manipulation and quality control."( Light effect on the stability of β-lapachone in solution: pathways and kinetics of degradation.
Cunha-Filho, MS; Echezarreta-López, MM; Estévez-Braun, A; Landín, M; Martínez-Pacheco, R; Pérez-Sacau, E, 2011
)
0.37
" Low water solubility and large therapeutic doses constitute the main problems to overcome in the development of dosage forms of this drug."( Fast dissolving β-lapachone particles and tablets: an approach using surface adsorption technique.
Cunha-Filho, MS; Landin, M; Martínez-Pacheco, R, 2012
)
0.38
"4) or in 1 M sodium salicylate, which agrees with the desired dosing sequence of the two drugs to exert synergistic pharmacologic effect at different cell checkpoints."( β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy.
Chen, Z; Gao, J; Liu, C; Qian, F; Yang, K; Zhang, L, 2015
)
0.42
" Electron microscopy analysis showed that beta-lapachone caused the development of the autophagosomes, and the frequency of the autophagosomes increased with increased dosage of beta-lapachone."( Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway, Reactive Oxygen Species (ROS) Production, and Autophagy Induction.
Han, Y; Li, J; Shi, D, 2019
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzochromenoneA benzochromene in which the heterotricyclic ring system is substituted by an oxo group.
orthoquinonesAny quinone in which the carbons of the two carbonyl groups in the quinone system are joined to each other by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (113)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency1.78580.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency3.54810.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency56.59850.125919.1169125.8920AID2549; AID2708
Chain A, Ferritin light chainEquus caballus (horse)Potency15.84895.623417.292931.6228AID2323
dopamine D1 receptorHomo sapiens (human)Potency0.46110.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency24.07930.100020.879379.4328AID488772; AID488773; AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency63.09570.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID493107
USP1 protein, partialHomo sapiens (human)Potency6.68000.031637.5844354.8130AID504865; AID540327
NFKB1 protein, partialHomo sapiens (human)Potency8.91250.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency12.58930.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency5.23000.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency3.84090.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency14.38220.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency1.58490.02517.304831.6228AID917; AID918
Smad3Homo sapiens (human)Potency3.16230.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency26.96800.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency31.62280.00137.762544.6684AID914; AID915
regulator of G-protein signaling 4Homo sapiens (human)Potency15.00300.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency19.04760.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.05500.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224823
67.9K proteinVaccinia virusPotency24.06820.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency23.10930.819914.830644.6684AID720573
arylsulfatase AHomo sapiens (human)Potency3.38081.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency8.91254.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency14.68920.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.84890.00207.533739.8107AID891
galactokinaseHomo sapiens (human)Potency35.48130.943115.289453.0367AID493189
hexokinase-4 isoform 1Homo sapiens (human)Potency6.51802.511913.800328.1838AID743205; AID743207
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency37.933023.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency5.01190.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.98110.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency31.62280.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency19.31730.354828.065989.1251AID504847; AID602199; AID602200; AID602201; AID602202
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency20.24660.010039.53711,122.0200AID1469
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
glucokinase regulatory proteinHomo sapiens (human)Potency6.51802.511913.800328.1838AID743205; AID743207
mitogen-activated protein kinase 1Homo sapiens (human)Potency35.71680.039816.784239.8107AID1454; AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency14.68920.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency12.37020.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency19.60670.00378.618923.2809AID2660; AID2668
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency19.01150.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency8.42790.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency4.06770.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency20.41140.004611.374133.4983AID463097; AID504364
survival motor neuron protein isoform dHomo sapiens (human)Potency18.29160.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency26.67950.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency21.90030.00419.962528.1838AID2675; AID493199; AID493205
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency11.51890.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency12.56200.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency3.16230.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency39.81070.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency5.23000.00339.158239.8107AID1347411
Integrin beta-3Homo sapiens (human)Potency5.01190.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency5.01190.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency22.38720.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency34.89800.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency22.38720.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency10.000028.183860.145389.1251AID1347427
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency37.93300.07578.474229.0628AID504547
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)3.00000.20001.95696.3096AID604082
Lysine-specific demethylase 4EHomo sapiens (human)Ki3.55001.92002.94504.3300AID604079
Cocaine esteraseHomo sapiens (human)Ki0.10900.00630.98358.0000AID1431883
Tyrosyl-DNA phosphodiesterase 2Homo sapiens (human)IC50 (µMol)0.97000.97002.21604.1000AID765294
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)13.33000.00402.92669.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)9.09000.00022.45859.9600AID1803986; AID1805801; AID1884001
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.10000.17004.559010.0000AID1594139
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)0.72000.05373.075710.0000AID1557371; AID1557391; AID1616267; AID1616268
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)Ki0.10000.09402.37907.0000AID1266385; AID1728744
NADHomo sapiens (human)IC50 (µMol)5.46670.00260.80763.4000AID1326420; AID1326421; AID1441543
Protein kinase C alpha typeHomo sapiens (human)IC50 (µMol)1.80000.00010.972010.0000AID1799534
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)IC50 (µMol)4.00000.00011.97318.0000AID1142307
Protein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)IC50 (µMol)1.80000.04502.67428.0000AID1799534
Liver carboxylesterase 1Homo sapiens (human)Ki1.22000.00252.01368.4800AID1431882
Caspase-1Homo sapiens (human)IC50 (µMol)1.69000.00201.70138.8000AID1801388
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)1.80000.02204.20249.4000AID1799534
Tyrosine-protein kinase JAK3Homo sapiens (human)IC50 (µMol)1.80000.00010.41937.9200AID1799534
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)2.10000.17004.559010.0000AID1594139
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)IC50 (µMol)4.00000.00011.80888.0000AID1142307
Transcription factor p65Homo sapiens (human)IC50 (µMol)4.00000.00011.89818.8000AID1142307
Receptor-type tyrosine-protein phosphatase etaHomo sapiens (human)IC50 (µMol)1.80001.00002.00003.0000AID1799534
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)0.12000.06003.96319.7000AID1594135
Receptor protein-tyrosine kinase Homo sapiens (human)IC50 (µMol)1.80000.04302.37495.9500AID1799534
60 kDa chaperonin Escherichia coliIC50 (µMol)0.94500.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)0.94500.03903.55529.8000AID1594140; AID1594141
Mucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)IC50 (µMol)1.55000.42001.81574.1000AID1256820; AID1256822
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (578)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
prostaglandin metabolic processCocaine esteraseHomo sapiens (human)
xenobiotic metabolic processCocaine esteraseHomo sapiens (human)
catabolic processCocaine esteraseHomo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
double-strand break repairTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
cell surface receptor signaling pathwayTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
negative regulation of DNA-templated transcriptionTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
neuron developmentTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
protein polyubiquitinationNADHomo sapiens (human)
response to ischemiaNADHomo sapiens (human)
NADH oxidationNADHomo sapiens (human)
ubiquinone metabolic processNADHomo sapiens (human)
xenobiotic metabolic processNADHomo sapiens (human)
nitric oxide biosynthetic processNADHomo sapiens (human)
response to oxidative stressNADHomo sapiens (human)
synaptic transmission, cholinergicNADHomo sapiens (human)
response to nutrientNADHomo sapiens (human)
response to toxic substanceNADHomo sapiens (human)
response to hormoneNADHomo sapiens (human)
response to carbohydrateNADHomo sapiens (human)
response to amineNADHomo sapiens (human)
removal of superoxide radicalsNADHomo sapiens (human)
protein catabolic processNADHomo sapiens (human)
response to estradiolNADHomo sapiens (human)
response to lipopolysaccharideNADHomo sapiens (human)
response to testosteroneNADHomo sapiens (human)
cellular response to oxidative stressNADHomo sapiens (human)
negative regulation of protein catabolic processNADHomo sapiens (human)
vitamin E metabolic processNADHomo sapiens (human)
vitamin K metabolic processNADHomo sapiens (human)
negative regulation of apoptotic processNADHomo sapiens (human)
response to alkaloidNADHomo sapiens (human)
positive regulation of neuron apoptotic processNADHomo sapiens (human)
innate immune responseNADHomo sapiens (human)
cell redox homeostasisNADHomo sapiens (human)
response to ethanolNADHomo sapiens (human)
response to electrical stimulusNADHomo sapiens (human)
cellular response to hydrogen peroxideNADHomo sapiens (human)
NADPH oxidationNADHomo sapiens (human)
cellular response to metal ionNADHomo sapiens (human)
negative regulation of ferroptosisNADHomo sapiens (human)
response to tetrachloromethaneNADHomo sapiens (human)
response to L-glutamineNADHomo sapiens (human)
response to hydrogen sulfideNADHomo sapiens (human)
response to flavonoidNADHomo sapiens (human)
xenobiotic metabolic processNADPH--cytochrome P450 reductaseHomo sapiens (human)
electron transport chainNADPH--cytochrome P450 reductaseHomo sapiens (human)
positive regulation of monooxygenase activityNADPH--cytochrome P450 reductaseHomo sapiens (human)
cellular organofluorine metabolic processNADPH--cytochrome P450 reductaseHomo sapiens (human)
response to hormoneNADPH--cytochrome P450 reductaseHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to lipopolysaccharideNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
JNK cascadeNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of gene expressionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of lipid storageNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of vitamin D biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of cholesterol transportNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of interleukin-12 productionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to muscle stretchNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of apoptotic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of inflammatory responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
B cell receptor signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
negative regulation of protein metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mammary gland involutionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of transcription initiation by RNA polymerase IINuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to mechanical stimulusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to nicotineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-1Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-6Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to tumor necrosis factorNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to dsRNANuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to interleukin-17Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to virusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
antibacterial innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of hyaluronan biosynthetic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to angiotensinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
positive regulation of miRNA metabolic processNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
gene expressionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
dopamine secretionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatin remodelingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
proteolysisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide cross-linkingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein deaminationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of apoptotic processProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of GTPase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of cell adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of neurogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of small GTPase mediated signal transductionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of mitochondrial calcium ion concentrationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
bone developmentProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
branching involved in salivary gland morphogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
salivary gland cavitationProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to cocaineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to dopamineProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
positive regulation of sprouting angiogenesisProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cellular response to serotoninProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
regulation of apoptotic cell clearanceProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
follicular dendritic cell differentiationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
germinal center formationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
extracellular matrix organizationNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to lipopolysaccharideNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
rhythmic processNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
spleen developmentNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cellular response to stressNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
innate immune responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
non-canonical NF-kappaB signal transductionNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
response to cytokineNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
inflammatory responseNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
positive regulation of interleukin-1 beta productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
positive regulation of amyloid-beta formationTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
liver developmentTranscription factor p65Homo sapiens (human)
hair follicle developmentTranscription factor p65Homo sapiens (human)
defense response to tumor cellTranscription factor p65Homo sapiens (human)
response to ischemiaTranscription factor p65Homo sapiens (human)
acetaldehyde metabolic processTranscription factor p65Homo sapiens (human)
chromatin organizationTranscription factor p65Homo sapiens (human)
DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
inflammatory responseTranscription factor p65Homo sapiens (human)
cellular defense responseTranscription factor p65Homo sapiens (human)
neuropeptide signaling pathwayTranscription factor p65Homo sapiens (human)
canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of cell population proliferationTranscription factor p65Homo sapiens (human)
response to xenobiotic stimulusTranscription factor p65Homo sapiens (human)
animal organ morphogenesisTranscription factor p65Homo sapiens (human)
response to UV-BTranscription factor p65Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionTranscription factor p65Homo sapiens (human)
positive regulation of gene expressionTranscription factor p65Homo sapiens (human)
positive regulation of Schwann cell differentiationTranscription factor p65Homo sapiens (human)
negative regulation of angiogenesisTranscription factor p65Homo sapiens (human)
cytokine-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
protein catabolic processTranscription factor p65Homo sapiens (human)
response to muramyl dipeptideTranscription factor p65Homo sapiens (human)
response to progesteroneTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-12 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-6 productionTranscription factor p65Homo sapiens (human)
positive regulation of interleukin-8 productionTranscription factor p65Homo sapiens (human)
response to insulinTranscription factor p65Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein sumoylationTranscription factor p65Homo sapiens (human)
response to cobalaminTranscription factor p65Homo sapiens (human)
toll-like receptor 4 signaling pathwayTranscription factor p65Homo sapiens (human)
intracellular signal transductionTranscription factor p65Homo sapiens (human)
cellular response to hepatocyte growth factor stimulusTranscription factor p65Homo sapiens (human)
response to muscle stretchTranscription factor p65Homo sapiens (human)
non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
vascular endothelial growth factor signaling pathwayTranscription factor p65Homo sapiens (human)
prolactin signaling pathwayTranscription factor p65Homo sapiens (human)
negative regulation of protein catabolic processTranscription factor p65Homo sapiens (human)
negative regulation of apoptotic processTranscription factor p65Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
response to amino acidTranscription factor p65Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor p65Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTranscription factor p65Homo sapiens (human)
regulation of inflammatory responseTranscription factor p65Homo sapiens (human)
positive regulation of T cell receptor signaling pathwayTranscription factor p65Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTranscription factor p65Homo sapiens (human)
response to cAMPTranscription factor p65Homo sapiens (human)
defense response to virusTranscription factor p65Homo sapiens (human)
cellular response to hydrogen peroxideTranscription factor p65Homo sapiens (human)
interleukin-1-mediated signaling pathwayTranscription factor p65Homo sapiens (human)
response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to lipopolysaccharideTranscription factor p65Homo sapiens (human)
cellular response to lipoteichoic acidTranscription factor p65Homo sapiens (human)
cellular response to peptidoglycanTranscription factor p65Homo sapiens (human)
cellular response to nicotineTranscription factor p65Homo sapiens (human)
cellular response to interleukin-1Transcription factor p65Homo sapiens (human)
cellular response to interleukin-6Transcription factor p65Homo sapiens (human)
cellular response to tumor necrosis factorTranscription factor p65Homo sapiens (human)
postsynapse to nucleus signaling pathwayTranscription factor p65Homo sapiens (human)
antiviral innate immune responseTranscription factor p65Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionTranscription factor p65Homo sapiens (human)
negative regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor p65Homo sapiens (human)
cellular response to angiotensinTranscription factor p65Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellTranscription factor p65Homo sapiens (human)
positive regulation of miRNA metabolic processTranscription factor p65Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTranscription factor p65Homo sapiens (human)
cellular response to stressTranscription factor p65Homo sapiens (human)
response to cytokineTranscription factor p65Homo sapiens (human)
innate immune responseTranscription factor p65Homo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
vasculogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
heart developmentReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
blood coagulationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell population proliferationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of platelet activationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of macrophage chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet formationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell growthReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell migrationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
glucose homeostasisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of vascular permeabilityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of MAP kinase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
oligodendrocyte differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phagocytosisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of calcium-mediated signalingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of focal adhesion assemblyReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
contact inhibitionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
B-1 B cell differentiationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of T cell cytokine productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
proteolysisMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
defense responseMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
response to fungusMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of protein ubiquitinationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of interleukin-1 beta productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of interleukin-2 productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
T cell proliferationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
negative regulation of apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
T cell receptor signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
regulation of T cell receptor signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
nuclear exportMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
proteolysis involved in protein catabolic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of T-helper 17 cell differentiationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
innate immune responseMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
B cell activationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (179)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
methylumbelliferyl-acetate deacetylase activityCocaine esteraseHomo sapiens (human)
carboxylesterase activityCocaine esteraseHomo sapiens (human)
carboxylic ester hydrolase activityCocaine esteraseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
magnesium ion bindingTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
single-stranded DNA bindingTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
transcription corepressor activityTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
nuclease activityTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
protein bindingTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
manganese ion bindingTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
tyrosyl-RNA phosphodiesterase activityTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
5'-tyrosyl-DNA phosphodiesterase activityTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
RNA bindingNADHomo sapiens (human)
cytochrome-b5 reductase activity, acting on NAD(P)HNADHomo sapiens (human)
superoxide dismutase activityNADHomo sapiens (human)
protein bindingNADHomo sapiens (human)
NADPH dehydrogenase (quinone) activityNADHomo sapiens (human)
identical protein bindingNADHomo sapiens (human)
NADH:ubiquinone reductase (non-electrogenic) activityNADHomo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityNADHomo sapiens (human)
NADPH-hemoprotein reductase activityNADPH--cytochrome P450 reductaseHomo sapiens (human)
protein bindingNADPH--cytochrome P450 reductaseHomo sapiens (human)
NADP bindingNADPH--cytochrome P450 reductaseHomo sapiens (human)
FMN bindingNADPH--cytochrome P450 reductaseHomo sapiens (human)
flavin adenine dinucleotide bindingNADPH--cytochrome P450 reductaseHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
transcription cis-regulatory region bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription coregulator activityNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
identical protein bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
actinin bindingNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
protein-glutamine gamma-glutamyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
calcium ion bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
GTP bindingProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptidase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
protein-glutamine glutaminase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone serotonyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
histone dopaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide noradrenalinyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
peptide histaminyltransferase activityProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
DNA-binding transcription factor activityNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
protein bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
transcription coactivator bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor p65Homo sapiens (human)
DNA bindingTranscription factor p65Homo sapiens (human)
chromatin bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor p65Homo sapiens (human)
protein bindingTranscription factor p65Homo sapiens (human)
enzyme bindingTranscription factor p65Homo sapiens (human)
protein kinase bindingTranscription factor p65Homo sapiens (human)
chromatin DNA bindingTranscription factor p65Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor p65Homo sapiens (human)
peptide bindingTranscription factor p65Homo sapiens (human)
phosphate ion bindingTranscription factor p65Homo sapiens (human)
identical protein bindingTranscription factor p65Homo sapiens (human)
protein homodimerization activityTranscription factor p65Homo sapiens (human)
actinin bindingTranscription factor p65Homo sapiens (human)
histone deacetylase bindingTranscription factor p65Homo sapiens (human)
NF-kappaB bindingTranscription factor p65Homo sapiens (human)
ankyrin repeat bindingTranscription factor p65Homo sapiens (human)
general transcription initiation factor bindingTranscription factor p65Homo sapiens (human)
DNA-binding transcription factor bindingTranscription factor p65Homo sapiens (human)
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
beta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
gamma-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
mitogen-activated protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
delta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
kinase activator activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protease bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
endopeptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cysteine-type endopeptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
ubiquitin-protein transferase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protein bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
peptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
small molecule bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
identical protein bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (126)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
endoplasmic reticulumCocaine esteraseHomo sapiens (human)
endoplasmic reticulum lumenCocaine esteraseHomo sapiens (human)
intracellular membrane-bounded organelleCocaine esteraseHomo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nucleusTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
nucleoplasmTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
nucleolusTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
cytoplasmTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
aggresomeTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
nuclear bodyTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
PML bodyTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
PML bodyTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
cytoplasmTyrosyl-DNA phosphodiesterase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
nucleusNADHomo sapiens (human)
cytoplasmNADHomo sapiens (human)
cytosolNADHomo sapiens (human)
dendriteNADHomo sapiens (human)
neuronal cell bodyNADHomo sapiens (human)
synapseNADHomo sapiens (human)
cytosolNADHomo sapiens (human)
endoplasmic reticulum membraneNADPH--cytochrome P450 reductaseHomo sapiens (human)
membraneNADPH--cytochrome P450 reductaseHomo sapiens (human)
intracellular membrane-bounded organelleNADPH--cytochrome P450 reductaseHomo sapiens (human)
cytosolNADPH--cytochrome P450 reductaseHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
mitochondrionNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytosolNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
secretory granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
specific granule lumenNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
chromatinNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
transcription regulator complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
I-kappaB/NF-kappaB complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
nucleusNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
NF-kappaB p50/p65 complexNuclear factor NF-kappa-B p105 subunitHomo sapiens (human)
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleusProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
endoplasmic reticulumProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cytosolProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
plasma membraneProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
focal adhesionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
collagen-containing extracellular matrixProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
extracellular exosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
chromatinProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
nucleosomeProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
mitochondrionProtein-glutamine gamma-glutamyltransferase 2Homo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytosolNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
chromatinNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
Bcl3/NF-kappaB2 complexNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
cytoplasmNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleusNuclear factor NF-kappa-B p100 subunit Homo sapiens (human)
nucleolusTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
glutamatergic synapseTranscription factor p65Homo sapiens (human)
nucleusTranscription factor p65Homo sapiens (human)
nucleoplasmTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
cytosolTranscription factor p65Homo sapiens (human)
NF-kappaB p50/p65 complexTranscription factor p65Homo sapiens (human)
NF-kappaB complexTranscription factor p65Homo sapiens (human)
chromatinTranscription factor p65Homo sapiens (human)
transcription regulator complexTranscription factor p65Homo sapiens (human)
cytoplasmTranscription factor p65Homo sapiens (human)
immunological synapseReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell-cell junctionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell surfaceReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
ruffle membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
fibrillar centerMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
nucleusMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cytoplasmMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cytosolMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
perinuclear region of cytoplasmMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
polkadotsMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
CBM complexMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protein-containing complexMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (586)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1154529Cytotoxicity against NQO-1 deficient human NCI-H596 cells assessed as inhibition of cell viability after 2 hrs by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID1356031Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 10 umol/L measured after 6 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1867412Indifferent antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as fractional inhibitory concentration incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID197657In vitro inhibition of RNA dependent DNA polymerase of Rauscher leukemia virus (RLV)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1867418Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1441540Substrate activity at recombinant human CPR expressed in baculovirus infected insect cells assessed as compound reduction rate by measuring NADPH consumption per umol of enzyme preincubated for 3 mins followed by NADPH addition measured for 5 mins at 2 se2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1597871Cytotoxicity against mouse J774.A1 cells measured after 24 hrs by resazurin based assay
AID1441543Substrate activity at NQO1 in human A549 cells assessed as NQO1-mediated two-electron reduction of compound by measuring cell growth inhibition treated for 24 hrs measured after 72 hrs by MTT assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID303292Inhibition of TPA-induced EBV-EA activation in Raji cells at 1000 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID327865Reversal of induction of PARP1 hyperactivation in NQO1 expressing human H596 cells assessed as PAR accumulation at 10 uM for 10 mins by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1740968Antitumor activity against human HepG2 cells xenografted in BALB/c athymic nude mouse assessed as tumor growth inhibition at 20 mg/kg, iv administered at 2 days interval 19 days by caliper method relative to control2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1867441Induction of morphological changes in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as decrease in cellular density at 200 ug/ml by calcofluor white dye based confocal laser scanning microscopy2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1616281Binding affinity to human IDO1 expressed in Escherichia coli Rosetta (DE3) assessed induction of shift in Soret peak in phosphate buffer at 200 uM measured over 4 hrs by UV-vis absorption spectroscopy2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID1858851Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID744765Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-sensitive Leishmania amazonensis MHOM/BR/1989/BA199 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1356029Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 umol/L measured after 8 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1142307Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11
Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-κB regulation.
AID1266385Noncompetitive inhibition of human recombinant IDO1 expressed in Escherichia coli by Michaelis-Menton nonlinear regression plot analysis in presence of L-tryptophan2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
AID1616282Binding affinity to human IDO1 expressed in Escherichia coli Rosetta (DE3) assessed induction of shift in Soret peak in phosphate buffer at 200 uM in presence of ascorbate and MB reductants measured over 4 hrs by UV-vis absorption spectroscopy2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID43532Cytotoxicity against leukemia CCRF-CEM cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1339225Antiproliferative activity against HEK293 cells after 48 hrs by SRB assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition.
AID327853Reversal of induction of NAD+ depletion in NQO1 expressing human A549 cells at 10 uM in presence of 40 uM dicoumarol by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1612408Substrate activity at recombinant human NQO1 assessed as ratio of Kcat to Km by measuring umol of NADPH utilized per umol of enzyme at 10 uM preincubated for 3 mins followed by NADPH addition and measured at 2 secs interval for 5 mins by Michaelis-Menten 2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID1616300Inhibition of full-length human IDO1 expressed in Escherichia coli Rosetta (DE3) assessed as reduction in kynurenine production at 0.5 to 1 uM pre-incubated for 120 mins in presence of ascorbate and MB reductants before jump dilution with incubation mediu2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID665100Growth inhibition of human HeLa cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1867406Indifferent antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as reduction in fungal growth incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1241976Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1597873Antimycobacterial activity against isoniazid resistant Mycobacterium tuberculosis H37Rv ATCC 27294 measured after 7 days by resazurin microtiter assay
AID751332Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced TNFalpha expression incubated for 2 hrs prior to LPS challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID765294Inhibition of TDP2 (unknown origin) using 4-nitrophenyl phenylphosphonate as substrate after 60 mins2013Journal of medicinal chemistry, Aug-22, Volume: 56, Issue:16
Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.
AID1597875Antimycobacterial activity against isoniazid resistant Mycobacterium tuberculosis measured after 7 days by resazurin microtiter assay
AID101010Cytotoxicity against melanoma LOXIMVI cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1356028Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 umol/L measured after 6 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1431884Inhibition of human liver CES1 expressed in baculovirus infected sf9 cells at 10 uM using o-nitrophenyl acetate as substrate monitored at 15 secs interval for 5 mins relative to control2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1431885Inhibition of human intestinal CES2 expressed in baculovirus infected sf9 cells at 10 uM using o-nitrophenyl acetate as substrate monitored at 15 secs interval for 5 mins relative to control2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1441541Selectivity ratio of compound reduction rate catalyzed by recombinant human NQO1 expressed in Escherichia coli to compound reduction rate catalyzed by recombinant human CPR expressed in baculovirus infected insect cells2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1778766Cytotoxicity against NQO1-deficient human NCI-H596 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID744772Antileishmanial activity against antimony-sensitive Leishmania infantum MCAN/BR/2002/BH400 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1867398Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader an2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1739272Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID567423DNA damage index, DNA damage in human HCT8 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1181063Antihyperproliferative activity against human HaCaT cells assessed as LDH release at 2 umol/L after 4 hrs2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones.
AID1181062Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Synthesis and structure-activity relationships of lapacho analogues. 2. Modification of the basic naphtho[2,3-b]furan-4,9-dione, redox activation, and suppression of human keratinocyte hyperproliferation by 8-hydroxynaphtho[2,3-b]thiophene-4,9-diones.
AID1356023Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 umol/L measured after 2 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis (Rvb = 97 to 98%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1867413Additive antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration index incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID277224Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line.
AID1616267Inhibition of purified human recombinant IDO1 expressed in Escherichia coli assessed as reduction in kynurenine production incubated up to 90 mins using L-Trp substrate by Ehrlich's reagent based spectrophotometry2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID301690Toxicity assessed as hemolytic activity against mouse erythrocyte2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID660266Trypanocidal activity against bloodstream form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs by neubauer chamber analysis2012European journal of medicinal chemistry, Jun, Volume: 52On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions.
AID1326397Cytotoxicity against human MDA-MB-435 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID102148Cytotoxicity against breast MDA-MB-435 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1241989Cytotoxicity against MDCK cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID451330Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1326420Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days by Hoechst 33258 staining based assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1858854Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1256822Inhibition of His-tagged human MALT1 (catalytic domain-339-719 aa) by fluorescence based assay using 25 uM Ac-LRSR-AMC as substrate2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
AID1867409Additive antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID665108Cell cycle arrest in human HBL100 cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID125286Inhibition of Rauscher leukemia virus in female BALB/c mice. Compound is administered perorally at 125 mg/kg for 5 days a week for 4 weeks (exp 2); treated/control= 48.5/31.61984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1597870Selectivity index, ratio of IC50 for mouse J774.A1 cells to MIC for Mycobacterium tuberculosis INH R2
AID672224Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1431889Inhibition of human liver CES1 expressed in U373MG cells assessed as oseltamivir carboxylate formation at 5 uM using oseltamivir as substrate preincubated for 30 mins followed by compound washout and subsequent compound/substrate addition measured after 32017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1612423Substrate activity at recombinant human NQO1 assessed as ROS generation by measuring umol of cytochrome c utilized per umol of enzyme at 10 uM measured at 2 secs interval for 5 mins in presence of NADPH2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID1356041Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 3 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 62%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID327857Reversal of induction of DNA damage in human A549 cells in presence of 3-aminobenzamide at 10 uM after 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID327834Cytotoxicity against NQO1 expressing human A549 cells after 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1739271Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1867442Induction of morphological changes in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as decrease in number of cells within biofilm at 200 ug/ml incubated for 48 hrs by SEM analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1778764Cytotoxicity against human A549/Taxol cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1499468Selectivity ratio for substrate activity at recombinant human NQO1 to substrate activity at human CPR2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1849851Oral bioavailability in human at 40 mg/kg2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1867388Antibiofilm activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in metabolic activity at highest concentration incubated for 48 hrs2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1657056Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells at 1 uM preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis relative to control2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID567424DNA damage index, DNA damage in human HCT8 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID324610Antitrypanosomal activity against Trypanosoma cruzi Tulahuen assessed as trypomastigote viability at 24.7 uM by MTT assay relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1616298Inhibition of full-length human IDO1 expressed in Escherichia coli Rosetta (DE3) assessed as reduction in kynurenine production at 0.5 to 1 uM pre-incubated for 120 mins before jump dilution with incubation medium containing L-Trp and further incubated fo2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID1293544Antiproliferative activity against apoptosis resistant human U373 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID1884001Inhibition of N-terminal 3xFlag-His6-tagged SARS-CoV-2 papain-like protease nsp3 (1564 to 1878 residues) expressed in baculovirus infected Sf9 insect cells using Pro3 as substrate by fluorescence based assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1235087Trypanocidal activity against Trypanosoma cruzi Y bloodstream trypomastigotes in presence of 10% mouse blood assessed as induction of parasite lysis incubated for 24 hrs by Neubauer chamber based cell counting method2015Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
Synthesis and anti-Trypanosoma cruzi activity of new 3-phenylthio-nor-β-lapachone derivatives.
AID672227Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID665107Cell cycle arrest in human WiDr cells assessed as accumulation at S phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID665101Growth inhibition of human SW1573 cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1356030Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 umol/L measured after 24 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID327849Reversal of PAR-polymer formation in NQO1 expressing human A549 cells at 10 uM in presence of 50 uM dicoumarol2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1356021Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1829801Antitumor activity against human A549 cells xenografted in BALB/c nude mouse assessed as tumor volume change at 30 mg/kg, ip administered for 21 days2021European journal of medicinal chemistry, Nov-15, Volume: 224Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics.
AID327860Reversal of induction of NAD+ depletion in NQO1 expressing human A549 cells at 6 uM in presence of 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID327864Induction of DNA damage in NQO1 expressing human A549 cells at 10 uM in presence of dicoumarol after 2 hrs by alkaline comet tail assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID702318Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular genera
AID1867447Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader analys2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1154528Cytotoxicity against NQO-1 rich human A549 cells assessed as inhibition of cell viability after 2 hrs by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID567412Induction of lipid peroxidation in human HL60 cells assessed as increase in TBARS formation at 5 uM after 24 hrs in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1154527Activity at human recombinant NQO1 assessed as oxidized NADPH level at 10 umol/L measured per umol enzyme by spectrophotometric analysis2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID751333Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced MMP-9 expression incubated for 2 hrs prior to LPS challenge measured after 24 hrs by gelatin zymographic analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID303293Inhibition of TPA-induced EBV-EA activation in Raji cells at 500 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1441533Selectivity ratio of IC50 for substrate activity at CPR in human L02 cells assessed as cell growth inhibition to IC50 for substrate activity at NQO1 in human A549 cells assessed as cell growth inhibition2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID567493Cytotoxicity against human PBMC cells after 72 hrs by Alamar Blue assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID744764Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-resistant Leishmania amazonensis MHOM/BR/1989/BA199 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID503306Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID451331Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1778768Selectivity index, ratio of IC50 for NQO1-deficient human NCI-H596 cells to IC50 for human A549 cells overexpressing NQO1 incubated for 72 hrs by MTT assay
AID327837Induction of oxidative stress in NQO1 expressing human A549 cells assessed as reactive oxygen species generation at 10 uM after 1 hr by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID303298Cell viability in Raji cells at 500 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1867426Effect on efflux pump function in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as accumulation of Nile red fluorescence incubated for 1 hr by fluorescence based assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1867391Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1739265Substrate activity at recombinant human C-terminal His-tagged NQO1 (1 to 274 residues) expressed in Escherichia coli assessed as enzyme activity by measuring oxidation of NADPH incubated for 5 mins measured per micromol of enzyme every 5 sec for 1 mins by2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1356048Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G0 phase at 30 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 3%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1356054Induction of superoxide generation in human K562 cells at 5 umol/L measured after 24 hrs by DHE staining based flow cytometry2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1739291Induction of ROS generation in human HepG2 cells at 5 uM by DCFH-DA staining based flow cytometry analysis2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1431886Selectivity ratio of Ki for human liver CES1 to Ki for human intestinal CES22017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID303297Cell viability in Raji cells at 1000 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID451343Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio after 48 hrs by trypan blue staining2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1356046Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 10 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1612411Cytotoxicity against NQO1 deficient human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID1356033Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 10 umol/L measured after 24 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1499467Substrate activity at human CPR expressed in baculovirus expression system assessed as reduction rate by measuring umol of NADPH utilized per umol of enzyme at 10 uM preincubated for 3 mins followed by NADPH addition measured at 2 secs interval for 5 mins2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1612407Substrate activity at recombinant human NQO1 assessed as ROS generation by measuring metabolic rate utilizing umol of NADPH per umol of enzyme at 10 uM preincubated for 3 mins followed by NADPH addition and measured at 2 secs interval for 5 mins2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID1326421Activation of NQO1 in human A549 cells assessed as decrease in cell survival incubated for 2 hrs measured after 7 days in presence of NQO1 inhibitor dicoumarol by Hoechst 33258 staining based assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1293545Antiproliferative activity against apoptosis resistant human A549 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID1499473Substrate activity at recombinant human NQO1 expressed in Escherichia coli assessed as Kcat to Km ratio at 10 uM preincubated for 3 mins followed by NADPH addition measured at 2 secs interval for 5 mins by UV-Vis spectroscopy2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID51423Compound is evaluated for activity (T/C) in peritoneal infected chickens with Rous Sarcoma virus S-R after peroral administration of 12 x 31.3 mg/kg (b.i.d); 18.4/8.81984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1356053Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs in presence of NQO1 inhibitor dicoumarol by DHE staining based flow cytometry2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID327840Induction of DNA damage in NQO1 deficient human H596 cells at 10 uM after 2 hrs by alkaline comet tail assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID665105Cell cycle arrest in human HeLa cells assessed as accumulation at S phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1860572Induction of reactive oxygen species production assessed as increase in hydrogen peroxide production using HRP as substrate in presence of DTT by redox cycling assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery, enantioselective synthesis of myrtucommulone E analogues as tyrosyl-DNA phosphodiesterase 2 inhibitors and their biological activities.
AID445403Toxicity in mouse erythrocytes assessed as hemolytic activity after 30 mins by spectrophotometry2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID380856Antiproliferative activity against human HaCaT cells1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID1612420Substrate activity at recombinant human NQO1 assessed as induction of ROS generation at 1 to 10 uM after 3 hrs by DCF-DA staining based fluorescence laser scanning confocal microscopic analysis2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID744771Antileishmanial activity against antimony-resistant Leishmania infantum MCAN/BR/2002/BH400 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID51425Compound is evaluated for activity (T/C) in peritoneal infected chickens with Rous Sarcoma virus S-R after peroral administration of 6 x 15.6 mg/kg (b.i.d); 12.0/8.81984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1867411Additive antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader 2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID90292Mean graph midpoint growth inhibition of human cancer cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID327844Induction of ATP depletion in NQO1 expressing human H596 cells at 10 uM by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID327863Induction of DNA damage in NQO1 expressing human H596 cells at 10 uM in presence of dicoumarol after 2 hrs by alkaline comet tail assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1356051Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 30 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 23%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1867462Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration index incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1866031Antiproliferative activity against NQO1-positive human A549 cells2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1869328Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID672965Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 50 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID145733Cytotoxicity against ovarian OVCAR-5 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID567496Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID327843Induction of PARP1 hyperactivation in NQO1 deficient human H596 cells assessed as PAR accumulation at 10 uM for 10 mins by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID301689Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1431887Inhibition of human AChE at 10 uM using acetylthiocholine as substrate by spectrophotometric method relative to control2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1867404Antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as reduction in fungal growth incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1241977Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1778767Cytotoxicity against NQO1-deficient human A549 cells assessed as reduction in cell viability pretreated with DIC followed by compound addition and incubated for 72 hrs by MTT assay
AID1499470Intrinsic solubility of the compound2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1867420Antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1241979Cytotoxicity against human HCT8 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID301683Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID1293547Antiproliferative activity against apoptosis resistant human SK-MEL-28 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID1293543Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID476716Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID1441529Substrate activity at CPR in human L02 cells assessed as CPR-mediated one-electron reduction of compound by measuring cell growth inhibition at 20 to 100 uM treated for >8 hrs measured after 72 hrs by MTT assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID604079Non-competitive inhibition of JMJD2E relative to alpha-ketoglutarate2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Inhibitors of histone demethylases.
AID1499552Selectivity ratio for substrate activity at recombinant human NQO1 to substrate activity at CBR (unknown origin)2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1256821Antiproliferative activity against human OCI-LY3 cells after 48 hrs by MTT assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
AID1867436Antibiofilm activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as inhibition of biofilm formation at 200 ug/ml incubated for 48 hrs2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID327836Induction of oxidative stress in NQO1 expressing human H596 cells assessed as reactive oxygen species generation at 10 uM after 1 hr by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1557391Inhibition of IDO1 in human IFN-gamma induced HeLa cells assessed as reduction in L-kynurenine formation incubated for 5 hrs2019MedChemComm, Oct-01, Volume: 10, Issue:10
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1441520Substrate activity at CPR in human L02 cells assessed as CPR-mediated one-electron reduction of compound by measuring ROS production after 1 to 3 hrs by DCFH-DA staining based flow cytometry2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1326399Cytotoxicity against NQO1-deficient human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID735528Ratio of cisplatin IC50 to compound IC50 for human WHCO1 cells after 24 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Cytotoxicity of lapachol, β-lapachone and related synthetic 1,4-naphthoquinones against oesophageal cancer cells.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1867437Antibiofilm activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as inhibition of biofilm formation at 200 ug/ml incubated for 48 hrs2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID324607Effect on oxygen uptake per mg of protein in Trypanosoma cruzi Tulahuen epimastigotes relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1568278Inhibition of NF-kappaB localization in nucleus of human L540 cells at 0.7 ug/ml measured after 5 to 24 hrs by DAPI staining immunofluorescence microscopy2019European journal of medicinal chemistry, Sep-15, Volume: 178Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action.
AID1356049Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 30 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 62%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID702317Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM after 4 hrs by UV method2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Synthesis and structure-activity relationships of lapacho analogues. 1. Suppression of human keratinocyte hyperproliferation by 2-substituted naphtho[2,3-b]furan-4,9-diones, activation by enzymatic one- and two-electron reduction, and intracellular genera
AID1867386Disruption of plasma membrane integrity in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fold increase in sytox green fluorescence intensity at 200 ug/ml incubated for 48 hrs by fluorescence based assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1608333Anti-parasitic activity against Trypanosoma cruzi after 24 hrs2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1326396Cytotoxicity against human SF295 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID327848Reversal of PAR-polymer formation in NQO1 expressing human H596 cells at 10 uM in presence of 50 uM dicoumarol2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID751336Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS expression incubated for 2 hrs prior to LPS challenge measured after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1612410Cytotoxicity against human A549 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID1356045Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 10 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 62%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1441521Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered every other day for 3 weeks measured twice per week during compound dosing relative to control2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1869325Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID567421DNA damage index, DNA damage in human MDA-MB-435 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID402601Cytotoxicity against etoposide-resistant human KB cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID301686Cytotoxicity against human SF295 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID1326393Cytotoxicity against NQO1-deficient human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1273040Solubility of compound in diluted hydrochloric acid buffer solution at pH 3 at 25 deg C for 8 hrs2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID1739260Selectivity index, ratio of GI50 for human A549 cells pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs to GI50 for human A549 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID389437Anticancer activity against human DU145 cells after 72 hrs by XTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
AID1739296Antitumor activity against human HepG2 cells xenografted in athymic nude mouse assessed as inhibition of tumor growth at 20 mg/kg, iv administered once every 2 days for 19 days by caliper analysis relative to control2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1499472Effective permeability of the compound at pH 7.4 by PAMPA assay2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID402597Cytotoxicity against human KB cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1616302Inhibition of full-length human IDO1 expressed in Escherichia coli Rosetta (DE3) assessed as reduction in kynurenine production at 0.5 to 1 uM pre-incubated for 120 mins in presence of ascorbate and MB reductants and catalase before jump dilution with inc2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID1869324Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID1867427Inhibition of fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter ATPase activity assessed as reduction in inorganic phosphate release in presence of ATP incubated for 1 hr by Fiske and Sub barrow method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID303300Cell viability in Raji cells at 10 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID402607Cytotoxicity against human 1A9 cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID481798Antitrypanosomal activity against Trypanosoma cruzi Y blood stream trypomastigotes after 24 hrs2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles.
AID445396Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID744770Antileishmanial activity against antimony-sensitive Leishmania amazonensis MHOM/BR/1989/BA199 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1867439Induction of morphological changes in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as decrease in biofilm thickness at 200 ug/ml by calcofluor white dye based confocal laser scanning microscopy2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1778757Cytotoxicity against human A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1356025Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 umol/L measured after 6 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis (Rvb = 97 to 98%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1191934Cytotoxicity against human A549 cells after 72 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
AID327841Induction of PARP1 hyperactivation in NQO1 expressing human H596 cells assessed as PAR accumulation at 10 uM for 10 mins by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1829800Antitumor activity against human A549 cells xenografted in BALB/c nude mouse assessed as tumor inhibition rate at 30 mg/kg, ip administered for 21 days2021European journal of medicinal chemistry, Nov-15, Volume: 224Rational designed highly sensitive NQO1-activated near-infrared fluorescent probe combined with NQO1 substrates in vivo: An innovative strategy for NQO1-overexpressing cancer theranostics.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID301685Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID1356039Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 1 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 23%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1241984Cytotoxicity against human SF295 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID386972Oxidation of dithiothreitol assessed as oxygen consumption at 50 uM2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Studies of trypanocidal (inhibitory) power of naphthoquinones: evaluation of quantum chemical molecular descriptors for structure-activity relationships.
AID1867419Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1740949Substrate activity at recombinant human C-terminal His-tagged NQO1 (1 to 274 residues) expressed in Escherichia coli assessed as metabolic rate by measuring NADPH oxidation per micromol protein at 10 mmol/L measured at 5 secs interval for 1 min by UV-Visi2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1778769Selectivity index, ratio of IC50 for human A549 cells overexpressing NQO1 to IC50 for NQO1-deficient human A549 cells assessed as reduction in cell viability pretreated with DIC followed by compound addition and measured after 72 hrs by MTT assay
AID1612499Substrate activity at recombinant human NQO1 assessed as ratio of number of equivalents of consumed NADPH to number of equivalents of test compound at 10 uM preincubated for 3 mins followed by NADPH addition and measured at 2 secs interval for 5 mins by M2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID476715Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID1415916Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi2017MedChemComm, May-01, Volume: 8, Issue:5
Synthesis and biological evaluation of
AID567498Induction of lipid peroxidation in human HL60 cells assessed as increase in TBARS formation at 5 uM after 24 hrs2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1241978Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID402599Cytotoxicity against vincristine-resistant human KBVIN cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID45941Cytotoxicity against CNS SF-295 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID327838Induction of DNA damage in NQO1 expressing human H596 cells at 10 uM after 2 hrs by alkaline comet tail assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID327867Reversal of induction of nucleotide depletion in NQO1 expressing human H596 cells in presence of 3-aminobenzamide by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1608336Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1867432Hemolytic activity in human erythrocytes assessed as haemoglobin release at 12.5 ug/ml incubated for 1 hr in presence of fluconazole by absorbance based method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1597872Selectivity index, ratio of IC50 for mouse J774.A1 cells to MIC for Mycobacterium tuberculosis H37Rv
AID567503Induction of lipid peroxidation in human SF295 cells assessed as increase in TBARS formation at 5 uM after 24 hrs in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID672222Antiproliferative activity against human OE21 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1867417Antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1867428Inhibition of fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter ATPase activity assessed as reduction in inorganic phosphate release in presence of ATP incubated for 1 hr by Fiske and Sub barrow method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID567422DNA damage index, DNA damage in human MDA-MB-435 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1597869Selectivity index, ratio of IC50 for mouse J774.A1 cells to MIC for Mycobacterium tuberculosis INH R1 ATCC 35822
AID1241981Cytotoxicity against human PC3M cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1778765Cytotoxicity against human DPP-resistant A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID567495Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1867422Induction of ROS generation in fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as fold increase in ROS level incubated for 90 mins by DCFH-DA dye based fluorescence assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID277223Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line.
AID665110Cell cycle arrest in human SW1573 cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID327866Reversal of induction of nucleotide depletion in NQO1 expressing human A549 cells in presence of 3-aminobenzamide by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID445397Cytotoxicity against human SF295 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID751328Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX-2 expression incubated for 2 hrs prior to LPS challenge measured after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1849849Volume of distribution at steady state in human2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID327862Induction of NAD+ depletion in NQO1 expressing human A549 cells at 6 uM after 1 hr by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID327856Reversal of induction of cell death in human A549 cells in presence of 3-aminobenzamide at 10 uM after 48 hrs by TUNEL assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1858852Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1499544Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 50 mg/kg, iv administered every other day for 3 weeks measured every day during compound dosing relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID672221Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID603333Antitrypanosomal activity against bloodstream trypomastigote form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
Synthesis and anti-Trypanosoma cruzi activity of β-lapachone analogues.
AID1326395Cytotoxicity against human PC3 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID1273047Binding affinity to recombinant human NQO1 assessed as induction of ROS generation by measuring reduction of cytochrome C per min per mg of NQO1 by spectrophotometric analysis2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID327845Induction of ATP depletion in NQO1 expressing human A549 cells at 10 uM by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1867385Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID672225Antiproliferative activity against human U373 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1849848Clearance in human2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID672967Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID1739299Selectivity index, ratio of GI50 for human HepG2 cells pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs to GI50 for human HepG2 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1293549Antiproliferative activity against apoptosis sensitive mouse B16F10 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID567491DNA damage index, DNA damage in human SF295 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID567501Induction of lipid peroxidation in human MDA-MB-435 cells assessed as increase in TBARS formation at 5 uM after 24 hrs in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID445394Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID476712Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID445398Cytotoxicity against human PBMC after 72 hrs by alamar blue assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID1356037Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G1 phase at 1 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 62%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1739274Cytotoxicity against human L02 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1431883Inhibition of human intestinal CES2 expressed in baculovirus infected sf9 cells using o-nitrophenyl acetate as substrate monitored at 15 secs interval for 5 mins2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1356044Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G0 phase at 10 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 3%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1866021Lipophilicity, logD of compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1466262Antihyperproliferative activity against human HaCaT cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Jul-07, Volume: 134Oxadiazole-substituted naphtho[2,3-b]thiophene-4,9-diones as potent inhibitors of keratinocyte hyperproliferation. Structure-activity relationships of the tricyclic quinone skeleton and the oxadiazole substituent.
AID1241983Cytotoxicity against human OVCAR8 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1867421Induction of ROS generation in fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as fold increase in ROS level incubated for 90 mins by DCFH-DA dye based fluorescence assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID744766Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-resistant Leishmania infantum MCAN/BR/2002/BH400 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1867407Additive antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader an2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID158816Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (expt 1)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID324608Effect on oxygen redox cycling in Trypanosoma cruzi Tulahuen assessed as oxygen consumption per mg of protein relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID481799Cytotoxicity against human PBMC after 72 hrs by alamar blue assay2010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles.
AID1241982Cytotoxicity against human OVCAR3 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID327842Induction of PARP1 hyperactivation in NQO1 expressing human A549 cells assessed as PAR accumulation at 10 uM for 10 mins by Western blot2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID51424Compound is evaluated for activity (T/C) in peritoneal infected chickens with Rous Sarcoma virus S-R after peroral administration of 12x15.6 mg/kg (b.i.d); 16.9/8.81984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID665099Growth inhibition of human HBL100 cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1867425Effect on efflux pump function in fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as accumulation of Nile red fluorescence incubated for 1 hr by fluorescence based assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID451340Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 100 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1869321Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1867399Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration in presence of fluconazole incubated for 48 hrs by checkboard assay based microplate 2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1356050Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 30 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1657057Inhibition of IL-6 induced STAT3 phosphorylation at Tyr705 residue in human MCF7 cells at 10 uM preincubated for 1 hr followed by IL-6 stimulation and measured after 1 hr by Western blot analysis relative to control2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID327847Induction of NAD+ depletion in NQO1 expressing human A549 cells at 10 uM by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID672219Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID476717Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID1441542Electrochemical behavior of the compound assessed as electrochemical redox potential with reference to ferrocene at 1 mM using Ag/AgCl reference electrode measured up to -2 V at potential sweep rates of 50 mV/s by cyclic voltammetry2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID402610Cytotoxicity against human HOS cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID744769Antileishmanial activity against antimony-resistant Leishmania amazonensis MHOM/BR/1989/BA199 promastigote infected in Swiss mouse peritoneal macrophages after 72 hrs2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1191936Selectivity ratio of IC50 for human A549 cells in presence of NQO1 inhibitor dicoumarol to IC50 for human A549 cells2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
AID744767Selectivity index, ratio of CC50 for Swiss mouse peritoneal macrophages to IC50 for antimony-sensitive Leishmania infantum MCAN/BR/2002/BH400 promastigote2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID567500Induction of lipid peroxidation in human SF295 cells assessed as increase in TBARS formation at 5 uM after 24 hrs2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1657059Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID125288Inhibition of Rauscher leukemia virus in female BALB/c mice. Compound is administered perorally at 125 mg/kg for 5 days a week for 4 weeks (exp 3); treated/control= 51.1/34.11984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID604082Inhibition of JMJD2E2011Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12
Inhibitors of histone demethylases.
AID303294Inhibition of TPA-induced EBV-EA activation in Raji cells at 100 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID672229Antiproliferative activity against human MCF7/AZ cells assessed as reduction in cell viability after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1431890Inhibition of human intestinal CES2 expressed in U373MG cells assessed as 7-ethyl-10-hydroxycamptothecin formation at 5 uM using irinotecan as substrate preincubated for 1 hr followed by substrate addition measured after 5 mins by HPLC method relative to 2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID445395Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
3-arylamino and 3-alkoxy-nor-beta-lapachone derivatives: synthesis and cytotoxicity against cancer cell lines.
AID1867416Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as reduction in fungal growth incubated for 48 hrs by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID451338Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 1000 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID567497Cytotoxicity against human SF295 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID567502Induction of lipid peroxidation in human HCT8 cells assessed as increase in TBARS formation at 5 uM after 24 hrs in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID327833Cytotoxicity against NQO1 deficient human H596 cells assessed as long term survival at >15 uM for 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID567420DNA damage index, DNA damage in human HL60 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID303295Inhibition of TPA-induced EBV-EA activation in Raji cells at 10 mol ratio/TPA relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1867395Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of lapachone by checkboard assay based microplate re2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1740944Antiproliferative activity against human NCI-H596 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID402614Cytotoxicity against human Caki1 cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1867387Antibiofilm activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as reduction in metabolic activity up to 200 ug/ml incubated for 48 hrs2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID672223Antiproliferative activity against human Hs683 cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1740948Selectivity index, ratio of IC50 for human L02 cells to IC50 for human A549 cells2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID301684Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID51426Compound is evaluated for activity (T/C) in peritoneal infected chickens with Rous Sarcoma virus S-R after peroral administration of 6 x 31.3 mg/kg (b.i.d); 17.4/8.81984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID301688Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID1867435Inhibition of fluconazole sensitive Candida glabrata ATCC 2001 bacterial cell adhesion to polystyrene at 200 ug/ml incubated for 90 mins by MTT assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID380857Cytotoxicity against human HaCaT cells assessed as LDH release at 2 uM1999Journal of natural products, Aug, Volume: 62, Issue:8
Potential antipsoriatic agents: lapacho compounds as potent inhibitors of HaCaT cell growth.
AID1431882Inhibition of human liver CES1 expressed in baculovirus infected sf9 cells using o-nitrophenyl acetate as substrate monitored at 15 secs interval for 5 mins2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
AID1867405Additive antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID672966Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by Neubauer counter-based microscopic analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID744768Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: synthesis of novel α- and nor-α-lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition.
AID1867440Induction of morphological changes in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as decrease in cell-cell adhesion at 200 ug/ml by calcofluor white dye based confocal laser scanning microscopy2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID476714Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID1273038Drug metabolism assessed as recombinant human NQO1-mediated NADPH oxidation to NADP+ per micromol of protein preincubated for 3 mins followed by NADPH addition measured at 2 s intervals for 5 mins by enzyme labelling instrument-based assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID665104Cell cycle arrest in human HBL100 cells assessed as accumulation at S phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1273041Lipophilicity, log D of compound at pH 7.42016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID1867429Inhibition of fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter ATPase activity assessed as reduction in inorganic phosphate release in presence of ATP incubated for 1 hr by Fiske and Sub barrow method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID402617Cytotoxicity against human U87MG cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1739273Cytotoxicity against human A549 cells assessed as reduction in cell growth pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID327839Induction of DNA damage in NQO1 expressing human A549 cells at 10 uM after 2 hrs by alkaline comet tail assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID567411Induction of lipid peroxidation in human MDA-MB-435 cells assessed as increase in TBARS formation at 5 uM after 24 hrs2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID327850Reversal of induction of ATP depletion in NQO1 expressing human H596 cells at 10 uM in presence of 40 uM dicoumarol by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1356024Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 umol/L measured after 4 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis (Rvb = 97 to 98%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID144959Cytotoxicity against lung NCI-H23 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1293551Antiproliferative activity against apoptosis sensitive human MCF7 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID665106Cell cycle arrest in human SW1573 cells assessed as accumulation at S phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1356036Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G0 phase at 1 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 3%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID665109Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1728744Inhibition of IDO1 (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.
AID1293548Antiproliferative activity against apoptosis sensitive human Hs683 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID327835Cytotoxicity against NQO1 expressing human H596 cells after 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1778762Cytotoxicity against NQO1-deficient human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID1273050Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as tumor proliferation rate at 30 mg/kg, iv administered every other day over 21 days relative to vehicle-treated control2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID1739268Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1356022Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1740967Induction of reactive oxygen species production in human NCI-H596 cells at 5 uM measured after 5 hrs by DCFH-DA staining based flow cytometry2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1354486Half life in athymic nude mouse blood2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
AID402615Cytotoxicity against human Caki1 cells at 10 uM after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID327858Reversal of cell death in human A549 cells at 10 uM in presence of 3-aminobenzamide after 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1869327Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID327854Reversal of PARP1 hyperactivation in NQO1 expressing human A549 cells assessed as PAR formation in presence of 3-aminobenzamide2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1849789Selectivity index, ratio of IC50 for human PBMC cells to IC50 for human HL-60 cells2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID451342Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID327846Induction of NAD+ depletion in NQO1 expressing human H596 cells at 10 uM by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1154525Activity at human recombinant NQO1 assessed as NADPH oxidation by spectrophotometric analysis2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID402612Cytotoxicity against human MCF7 cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1657061Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1778755Substrate activity at recombinant human NQO1 assessed as catalytic efficiency preincubated for 3 mins followed by NADPH addition and measured at 2 sec interval for 5 mins
AID1441531Substrate activity at NQO1 in human A549 cells assessed as NQO1-mediated two-electron reduction of compound by measuring ROS production after 1 to 3 hrs by DCFH-DA staining based flow cytometry2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1867384Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1849850Elimination half life in human at 1.5 mg/kg, iv2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1867446Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1191935Cytotoxicity against human A549 cells after 72 hrs by MTT assay in presence of NQO1 inhibitor dicoumarol2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
AID301687Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone.
AID1273049Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered every other day over 21 days relative to vehicle control2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID38013In vitro inhibition of RNA dependent DNA polymerase of Avian myeloblastosis virus (AMV)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1739301Selectivity index, ratio of GI50 for human A549 cells pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs to GI50 for human A549 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1740947Selectivity index, ratio of IC50 for human A549 cells in presence of NQO1 inhibitor dicoumarol to IC50 for human A549 cells2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID386974Antitrypanosomal activity against Leptomonas seymouri2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Studies of trypanocidal (inhibitory) power of naphthoquinones: evaluation of quantum chemical molecular descriptors for structure-activity relationships.
AID1867463Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as fractional inhibitory concentration index incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID197656Maximum tolerated dose (MTD, po) for prolongation of survival in mice infected with Rauscher leukemia virus1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1354487Aqueous solubility of the compound in water2018Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
AID1499469Lipophilicity, log D of the compound at pH 7.42017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID402603Cytotoxicity against camptothecin-resistant human KB cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1867392Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as reduction in fungal growth incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1867415Antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as reduction in fungal growth at lower concentration incubated for 48 hrs by serial dilution method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1356027Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 umol/L measured after 24 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis (Rvb = 97 to 98%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1778763Selectivity index, ratio of IC50 for NQO1-deficient human L02 cells to IC50 for human A549 cells overexpressing NQO1 incubated for 72 hrs by MTT assay
AID1867400Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as fractional inhibitory concentration in presence of fluconazole incubated for 48 hrs by checkboard assay based microplate 2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1739300Selectivity index, ratio of GI50 for human HepG2 cells pretreated for 1 hr with ROS scavenger, N-acetyl cysteine followed by incubation with compound for 48 hrs to GI50 for human HepG2 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1867449Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration index incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1867410Indifferent antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1557371Inhibition of recombinant human IDO1 expressed in Escherichia coli assessed as reduction in formation of kynurenine using L-tryptophan as substrate measured up to 90 mins by spectrophotometric method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID1849852Aqueous solubility of the compound2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID1499491Substrate activity at NQO1 in human A549 cells assessed as induction of enzyme-catalyzed lipid peroxidation by measuring MDA equivalents per protein at 10 uM after 24 hrs by TBARS assay (Rvb = 3.53 +/- 1.12 nmol/mg)2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID51427Compound is evaluated for activity (T/C) in peritoneal infected chickens with Rous Sarcoma virus S-R after peroral administration of 6 x 31.3 mg/kg (b.i.d); 17.6/10.81984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID751325Inhibition of p38 MAPK phosphorylation in LPS-induced mouse RAW264.7 cells incubated for 2 hrs prior to LPS challenge measured after 24 hrs by Western blot analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1154530Selectivity ratio of IC50 for NQO-1 deficient human NCI-H596 cells to IC50 for NQO-1 rich human A549 cells2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID327861Reversal of cell death in NQO1 expressing human A549 cells at 6 uM in presence of 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1657060Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay2020Bioorganic & medicinal chemistry, 03-15, Volume: 28, Issue:6
STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.
AID1356042Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 3 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1293546Antiproliferative activity against apoptosis resistant human OE21 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID57726Cytotoxicity against prostate DU-145 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1273039Intrinsic aqueous solubility of compound by Avdeef-Bucher potentiometric titration assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID665102Growth inhibition of human WiDr cells by SRB assay2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1740966Induction of reactive oxygen species production in human HepG2 cells at 5 uM measured after 5 hrs by DCFH-DA staining based flow cytometry2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID402609Cytotoxicity against paclitaxel-resistant human 1A9 cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1867434Inhibition of fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter bacterial cell adhesion to polystyrene at 200 ug/ml incubated for 90 mins by MTT assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1778756Substrate activity at recombinant human NQO1 assessed as enzymatic reduction rate at 10 uM
AID303299Cell viability in Raji cells at 100 mol ratio/TPA by tryptan blue staining relative to control2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID1326398Cytotoxicity against human OVCAR8 cells overexpressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID665111Cell cycle arrest in human WiDr cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1326394Cytotoxicity against human HCT116 cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.
AID386973Oxidation of dihydrolipoamide assessed as oxygen consumption at 50 uM2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Studies of trypanocidal (inhibitory) power of naphthoquinones: evaluation of quantum chemical molecular descriptors for structure-activity relationships.
AID1869323Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID1849858Antitrypanosomal activity against bloodstream form of Trypanosoma cruzi Y trypomastigotes infected in albino mouse assessed as reduction in viable parasite in blood incubated for 24 hrs by Neubauer counting chamber method2021European journal of medicinal chemistry, Jan-15, Volume: 210A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.
AID303296Inhibition of TPA-induced EBV-EA activation in Raji cells2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from Tabebuia avellanedae.
AID327851Reversal of induction of ATP depletion in NQO1 expressing human A549 cells at 10 uM in presence of 40 uM dicoumarol by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1499486Substrate activity at NQO1 in human A549 cells assessed as induction of enzyme-catalyzed ROS production at 10 uM after 1 to 3 hrs by DCFH-DA-based flow cytometry2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1867414Indifferent antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as fractional inhibitory concentration index incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1356038Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at S phase at 1 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID125151Inhibition of Rauscher leukemia virus in female BALB/c mice. Compound is administered perorally at 125 mg/kg for 5 days a week for 4 weeks (exp 1); treated/control= 34.8/26.01984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
beta-Lapachone: synthesis of derivatives and activities in tumor models.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1867403Antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1739270Cytotoxicity against human HepG2 cells assessed as reduction in cell growth pretreated for 1 hr with NQO1 inhibitor, dicoumarol followed by incubation with compound for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID158817Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (expt 2)2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID327852Reversal of induction of NAD+ depletion in NQO1 expressing human H596 cells at 10 uM in presence of 40 uM dicoumarol by luciferase based bioluminescence assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1740943Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID567419DNA damage index, DNA damage in human HL60 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1356040Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G0 phase at 3 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 3%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1867423Induction of ROS generation in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p assessed as fold increase in ROS level incubated for 90 mins by DCFH-DA dye based fluorescence assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1241980Cytotoxicity against human PC3 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1869326Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID1739267Cytotoxicity against NQO1-rich human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID1869322Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay2022Journal of natural products, 06-24, Volume: 85, Issue:6
Identification and Characterization of Natural and Semisynthetic Quinones as Aurora Kinase Inhibitors.
AID567492DNA damage index, DNA damage in human SF295 cells to DNA damage in human HL60 cells with FPG/ENDO3 DNA repair enzymes in presence of N-acetylcytosine2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1293550Antiproliferative activity against apoptosis sensitive human PC3 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Mar-15, Volume: 26, Issue:6
Isatin derivatives with activity against apoptosis-resistant cancer cells.
AID735529Cytotoxicity against human WHCO1 cells after 24 hrs by MTT assay2013European journal of medicinal chemistry, Apr, Volume: 62Cytotoxicity of lapachol, β-lapachone and related synthetic 1,4-naphthoquinones against oesophageal cancer cells.
AID1241985Cytotoxicity against human MDA-MB-435 cells assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID751339Cytotoxicity against mouse RAW264.7 cells assessed as cell viability after 24 hrs by MTS assay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1441532Substrate activity at CPR in human L02 cells assessed as CPR-mediated one-electron reduction of compound by measuring cell growth inhibition treated for 24 hrs measured after 72 hrs by MTT assay2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID1256820Inhibition of MALT1 in human Jurkat cell lysate preincubated for 2 hrs followed by addition of 25 uM Ac-LRSR-AMC substrate for 3 hrs by fluorescence based assay2015Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21
Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
AID1273042Cytotoxicity against human A549 cells expressing NQO1 after 2 hrs by MTT assay2016Bioorganic & medicinal chemistry, Mar-01, Volume: 24, Issue:5
Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation.
AID451339Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 500 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID751340Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1499489Induction of intracellular ROS levels in human L02 cells at 10 uM after 1 to 3 hrs by DCFH-DA-based flow cytometry2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1356047Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 10 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 23%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1867393Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader anal2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1356052Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs by DHE staining based flow cytometry2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1441539Substrate activity at recombinant human NQO1 expressed in Escherichia coli assessed as compound reduction rate by measuring NADPH consumption per umol of enzyme preincubated for 3 mins followed by NADPH addition measured for 5 mins at 2 sec time interval 2017European journal of medicinal chemistry, Mar-31, Volume: 129Discovery of quinone-directed antitumor agents selectively bioactivated by NQO1 over CPR with improved safety profile.
AID451341Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells assessed as EA induction at 10 molar ratio after 48 hrs by immunofluorescence technique relative to 12-O-tetradecanoylphorbol-13-acetate2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1867448Indifferent antifungal activity against fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate read2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1867390Disruption of plasma membrane integrity in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fold increase in sytox green fluorescence intensity at 50 ug/ml incubated for 48 hrs by fluorescence based assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1867408Indifferent antifungal activity against fluconazole sensitive Candida glabrata ATCC 2001 assessed as fractional inhibitory concentration incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader analysis2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID567494Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1356026Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 umol/L measured after 8 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis (Rvb = 97 to 98%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID46277Cytotoxicity against colon COKI 205 cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1499471Solubility of the compound in diluted HCl buffer at pH 32017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1597874Antimycobacterial activity against isoniazid resistant Mycobacterium tuberculosis ATCC 35822 after 7 days by resazurin microtiter assay
AID1356032Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 10 umol/L measured after 8 hrs by annexin-V-FITC/7-AAD staining based flow cytometric analysis relative to control2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1858853Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1339226Inhibition of topoisomerase-2 in human FADU cells at 2 times antiproliferative IC50 after 24 hrs by ELISA relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Synthesis of pharmacologically important naphthoquinones and anticancer activity of 2-benzyllawsone through DNA topoisomerase-II inhibition.
AID476713Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay2010Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7
Antiproliferative activity of synthetic naphthoquinones related to lapachol. First synthesis of 5-hydroxylapachol.
AID672220Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID1499543Antitumor activity against human A549 cells xenografted in athymic nude mouse assessed as tumor growth inhibition at 30 mg/kg, iv administered every other day for 3 weeks measured every day during compound dosing relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1739269Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Jul-15, Volume: 198Design, synthesis, and biological evaluation of 4-substituted-3,4-dihydrobenzo[h]quinoline-2,5,6(1H)-triones as NQO1-directed antitumor agents.
AID672226Induction of apoptosis in human Jurkat cells assessed as apoptotic cells at 50 uM after 24 hrs using annexin-V/Propidium iodide by flow cytometry2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID567499Induction of lipid peroxidation in human HCT8 cells assessed as increase in TBARS formation at 5 uM after 24 hrs2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Synthesis and evaluation of quinonoid compounds against tumor cell lines.
AID1616268Inhibition of IDO1 in IFNgamma-induced human HeLa cells incubated for 5 hrs by Ehrlich's reagent based assay2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
AID1740946Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1740945Antiproliferative activity against human A549 cells measured after 48 hrs in presence of NQO1 inhibitor dicoumarol by MTT assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1867397Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of fluconazole by checkboard assay based microplate reader an2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1241986Cytotoxicity against human PBMC assessed as cell viability after 72 hrs by MTT assay2015European journal of medicinal chemistry, Aug-28, Volume: 101Hybrid compounds with two redox centres: modular synthesis of chalcogen-containing lapachones and studies on their antitumor activity.
AID1867424Effect on efflux pump function in fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr1p transporter assessed as accumulation of Nile red fluorescence incubated for 1 hr by fluorescence based assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID200454Cytotoxicity against renal SN12C cell lines2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
Preparation and cytotoxicity toward cancer cells of mono(arylimino) derivatives of beta-lapachone.
AID1740942Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID665120Inhibition of human topoisomerase 2alpha-mediated kDNA decatenation2012European journal of medicinal chemistry, Jul, Volume: 53β-Lapachone analogs with enhanced antiproliferative activity.
AID1356043Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at G2 phase at 3 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 23%)2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1867430Hemolytic activity in human erythrocytes assessed as haemoglobin release at 12.5 ug/ml incubated for 1 hr by absorbance based method2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID1191933Activity of human recombinant NQO1 assessed as ratio of kcat to Km preincubated for 3 mins before NADPH addition at 0.1 to 5 umol/L by NADPH recycling assay2015Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
AID1608334Potency index, ratio of beta-lapachone IC50 to compound IC50 for Trypanosoma cruzi after 24 hrs2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.
AID1867438Induction of ROS generation in fluconazole resistant Candida glabrata 109 overexpressing CgCdr1p transporter assessed as fold increase in ROS production at 200 ug/ml incubated for 48 hrs by DCFH-DA dye based fluorescence assay2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID402605Cytotoxicity against human A549 cells after 3 days by SRB assay2004Journal of natural products, Jun, Volume: 67, Issue:6
Antitumor agents. 233. Lantalucratins A-F, new cytotoxic naphthoquinones from Lantana involucrata.
AID389438Anticancer activity against human DU145 cells after 72 hrs 25 ug/ml by XTT assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol.
AID1612412Selectivity ratio of IC50 for NQO1 deficient human L02 cells to IC50 for human A549/TR cells expressing NQO12018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID327832Cytotoxicity against NQO1 expressing human H596 cells assessed as long term survival at =>5 uM for 2 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1858855Antimalarial activity against Plasmodium falciparum W2 incubated for 24 hrs2021European journal of medicinal chemistry, Jan-15, Volume: 210Antimalarial application of quinones: A recent update.
AID1356055Induction of superoxide generation in human K562 cells at 5 umol/L measured after 24 hrs in presence of NQO1 inhibitor dicoumarol by DHE staining based flow cytometry2018Journal of natural products, 07-27, Volume: 81, Issue:7
Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
AID324605Growth inhibition of Trypanosoma cruzi Tulahuen epimastigotes assessed as drug level causing decrease in growth constant2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1154526Ratio of Kcat to Km for human recombinant NQO1 by Michaelis-Menten analysis2014European journal of medicinal chemistry, Jul-23, Volume: 822-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID751330Antiinflammatory activity in mouse RAW264.7 cells assessed as downregulation of LPS-induced iNOS mRNA expression incubated for 2 hrs prior to LPS challenge measured after 9 hrs by RT-PCR analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1499548Hepatotoxicity in 48 hrs post fertilized transgenic liver zebrafish larvae model expressing LFABP:EGFP protein at 1 uM measured after 48 hrs post dose by fluorescence based assay2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1867394Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as reduction in fungal growth incubated for 48 hrs in presence of lapachone by checkboard assay based microplate reader anal2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID672228Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
Structural simplification of bioactive natural products with multicomponent synthesis. 4. 4H-pyrano-[2,3-b]naphthoquinones with anticancer activity.
AID158818Inhibition of Plasmodium berghei infection in mice (Mus musculus) at 200 mg/kg peroral dose (experiment 3); Not determined2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro and Plasmodium berghei in vivo.
AID327859Reversal of PARP1 hyperactivation in NQO1 expressing human A549 cells assessed as PAR formation at 6 uM in presence of 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID1867396Synergistic antifungal activity against fluconazole resistant Saccharomyces cerevisiae overexpressing CgCdr2p transporter assessed as fractional inhibitory concentration incubated for 48 hrs in presence of lapachone by checkboard assay based microplate re2022Bioorganic & medicinal chemistry, 06-01, Volume: 63Effects of β-lapachone and β-nor-lapachone on multidrug efflux transporters and biofilms of Candida glabrata.
AID451329Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay2009Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17
Synthesis and evaluation of bioactive naphthoquinones from the Brazilian medicinal plant, Tabebuia avellanedae.
AID1612409Cytotoxicity against human A549/TR cells expressing NQO1 assessed as reduction in cell viability after 72 hrs by MTT assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
AID327855Reversal of PARP1 hyperactivation in NQO1 expressing human H596 cells assessed as PAR formation in presence of 3-aminobenzamide2007Proceedings of the National Academy of Sciences of the United States of America, Jul-10, Volume: 104, Issue:28
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
AID751338Induction of nitric oxide scavenging activity assessed as nitrite level at 10 uM at room temperature after 60 mins by Griess assay in presence of light and SNP2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID1499466Substrate activity at recombinant human NQO1 expressed in Escherichia coli assessed as reduction rate by measuring umol of NADPH utilized per umol of enzyme at 10 uM preincubated for 3 mins followed by NADPH addition measured at 2 secs interval for 5 mins2017European journal of medicinal chemistry, Sep-29, Volume: 1382-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID18039863CLpro enzyme assay from Article 10.1101/2020.07.17.207019: \\Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.\\2020bioRxiv : the preprint server for biology, Aug-11Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
AID1799534BP Incorporation Assay from Article 10.1016/j.chembiol.2008.07.015: \\Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.\\2008Chemistry & biology, Sep-22, Volume: 15, Issue:9
Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (434)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (4.84)18.7374
1990's30 (6.91)18.2507
2000's109 (25.12)29.6817
2010's203 (46.77)24.3611
2020's71 (16.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.28 (24.57)
Research Supply Index6.10 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index49.81 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.45%)5.53%
Reviews31 (7.03%)6.00%
Case Studies1 (0.23%)4.05%
Observational0 (0.00%)0.25%
Other407 (92.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Dose Double-blind,Placebo-controlled,Single Dosing,Dose-escalation Clinical Trial to Investigate the Safety,Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects [NCT01285388]Phase 150 participants (Actual)Interventional2010-07-31Completed
A Phase I Clinical Trial to Evaluate the Pharmacokinetics and Safety of MB12066 in Healthy Male Volunteers [NCT02338856]Phase 111 participants (Actual)Interventional2015-01-31Completed
An Extension Study for Patients Previously Treated With ARQ 501 [NCT00622063]Phase 1/Phase 21 participants (Actual)Interventional2006-12-31Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis [NCT02029586]Phase 218 participants (Actual)Interventional2013-01-31Terminated(stopped due to Lack of recruitment)
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors [NCT00524524]Phase 19 participants (Actual)Interventional2007-08-31Completed
A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors [NCT01502800]Phase 191 participants (Actual)Interventional2011-12-29Completed
A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors [NCT00075933]Phase 180 participants Interventional2003-09-30Completed
A Phase Ib Safety and Pharmacokinetic Study of ARQ 501 in Combination With Docetaxol in Adult Patients With Locally Advanced or Metastatic Carcinoma [NCT00099190]Phase 150 participants Interventional2004-12-31Completed
A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma [NCT00102700]Phase 266 participants Interventional2005-01-31Completed
A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma [NCT00310518]Phase 230 participants Interventional2006-02-28Completed
A Dose Block-randomized, Double-blind, Placebo-controlled, Single or Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of MB12066 in Healthy Male Subjects [NCT01444677]Phase 140 participants (Anticipated)Interventional2011-04-30Completed
A Phase 2 Study of ARQ 501 in Patients With Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00358930]Phase 260 participants Interventional2006-07-31Completed
A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer [NCT02514031]Phase 117 participants (Actual)Interventional2016-03-24Terminated(stopped due to The study placed on temporarily hold to enrollment due to quality testing necessary for the study drug.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]